- Home
- NOG vs IBRX Comparison
NOG vs IBRX Comparison
Compare NOG & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NOG | IBRX |
|---|---|---|
| Founded | 2006 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.3B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NOG | IBRX |
|---|---|---|
| Price | $22.59 | $2.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | ★ $29.86 | $9.71 |
| AVG Volume (30 Days) | 2.3M | ★ 11.5M |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | ★ 7.96% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.82 | N/A |
| Revenue | ★ $2,050,402,000.00 | $82,555,000.00 |
| Revenue This Year | $20.20 | $667.18 |
| Revenue Next Year | N/A | $88.32 |
| P/E Ratio | $12.43 | ★ N/A |
| Revenue Growth | 2.50 | ★ 1025.95 |
| 52 Week Low | $19.88 | $1.83 |
| 52 Week High | $42.35 | $4.27 |
Technical Indicators
Market Signals| Indicator | NOG | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 48.57 | 56.50 |
| Support Level | $20.87 | $2.17 |
| Resistance Level | $24.77 | $2.40 |
| Average True Range (ATR) | 0.86 | 0.15 |
| MACD | 0.07 | 0.03 |
| Stochastic Oscillator | 40.83 | 72.22 |
Price Performance
Historical ComparisonAbout NOG Northern Oil and Gas Inc.
Northern Oil & Gas Inc is an independent energy company engaged in the acquisition, exploration, development, and production of crude oil and natural gas properties. Its principal business is crude oil and natural gas exploration, development, and production. The company's oil and natural gas sales come from three geographic areas in the United States: the Williston Basin (North Dakota and Montana), the Permian Basin (New Mexico and Texas), the Uinta Basin, and the Appalachian Basin (Pennsylvania and Ohio).
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.